Patterns of convergence and divergence between bipolar disorder type I and type

II: evidence from integrative genomic analyses

Yunqi Huang^{1,2}, Yunjia Liu^{1,2}, Yulu Wu^{1,2}, Yiguo Tang^{1,2}, Siyi Liu^{1,2}, Liling Xiao^{1,2}, Mengting Zhang^{1,2}, Shiwan Tao^{1,2}, Min Xie^{1,2}, Minhan Dai^{1,2}, Mingli Li^{1,2}, Hongsheng Gui^{3,4*}, Qiang Wang^{1,2*}

1. Mental Health Center and Psychiatric Laboratory, State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu, Sichuan, China
2. West China Brain Research Center, West China Hospital of Sichuan University, Chengdu, Sichuan, China
3. Center for Health Policy & Health Services Research, Henry Ford Health System, Detroit, MI, USA.
4. Behavioral Health Services, Henry Ford Health System, Detroit, MI, USA.

* Correspondence:

Hongsheng Gui, Behavioral Health Services, Henry Ford Health System, 1 Ford Place, 3A, Detroit, MI 48202, USA; +1-313-874-3042 (Tel), hgui1@hfhs.org ([Email](#))

Qiang Wang, West China Hospital, Sichuan University, Dianxin South Street 28, Chengdu, Sichuan, China; +86-28-85423651 (Tel), wangqiang130@scu.edu.cn ([Email](#))

Abstract

1 Genome-wide association studies (GWAS) analyses have revealed genetic evidence of bipolar
2 disorder (BD), but little is known about genetic structure of BD subtypes. We aimed to investigate
3 genetic overlap and distinction of bipolar type I (BDI) & type II (BDII) by conducting integrative
4 post-GWAS analyses. This study utilized single nucleotide polymorphism (SNP)-level approaches
5 to uncover correlated and distinct genetic loci. Transcriptome-wide association analyses (TWAS)
6 were then approached to pinpoint functional genes expressed in specific brain tissues and blood.
7 Next, we performed cross-phenotype analysis including exploring the potential causal associations
8 between BDI & II and drug responses and comparing the difference of genetic structures among
9 four different psychiatric traits. Our results find SNP-level evidence revealed three genomic loci,
10 *SLC25A17*, *ZNF184* and *RPL10AP3* shared by BDI & II, while one locus (i.e., *MAD1L1*) and
11 significant gene sets involved in calcium channel activity, neural and synapsed signals that
12 distinguished two subtypes. TWAS data implicated different genes effecting BDI & II through
13 expression in specific brain regions (e.g., nucleus accumbens for BDI). Cross-phenotype analyses
14 indicated that BDI & II share continuous genetic structures with schizophrenia (SCZ) and major
15 depression disorder (MDD), which help fill the gaps left by the dichotomy of mental disorder.
16 These combined evidences illustrate genetic convergence and divergence between BDI & II and
17 provide an underlying biological and trans-diagnostic insight into major psychiatric disorders.
18

1 Introduction

2 Bipolar disorder (BD) is one of the most severe psychiatric disorders, characterized by mood
3 states fluctuation. As one of the top causes of disability worldwide, BD affects more than 40
4 million people worldwide with the lifespan prevalence among 1%~4%^{1, 2}, early onset in
5 adolescents, and elevated risk of suicide³.

6 Population and molecular studies have proved evidence into the complex etiology of BD. Twin
7 and family studies have estimated that the heritability of BD is over 70%^{4,5} GWAS have brought
8 deeper insights to BD^{6,7} compared with previous population genetics studies⁸⁻¹⁰. The largest-scale
9 GWAS of BD was recently processed by Psychiatric Genomic Consortium Bipolar Disorder
10 Working Group (PGC3 BD)¹¹ and 64 genome-wide significant loci were identified. However, it
11 failed to display increasing of single nucleotide polymorphism (SNP)-level heritability (h^2_{SNP}) of
12 BD^{11, 12}.

13 BD can be categorized into several major subtypes: BD type I (BDI) and type II (BDII),
14 cyclothymia, and other specified bipolar and related disorder, according to the Diagnostic and
15 Statistical Manual Disorders, Fifth Edition (DSM-5)⁸. BDI requires manic episodes at least once
16 despite depression states, and BDII, is defined as more than one depressive and hypomanic state.
17 The lifetime prevalence of BDI (0.4%-1.2%)^{1, 2, 13} differs from BDII (0.1%-2.5%)^{1, 2, 13} in
18 worldwide. In addition, clinical presentations and severity vary in two subtypes^{1,14}, however, their
19 biological differences remained unclear due to insufficient sample size or substandard clinical
20 classification^{15, 16}.

21 Under the dichotomic diagnostic system, BD is hard to be distinguished from schizophrenia (SCZ),
22 and major depression disorder (MDD). BD with psychotic symptoms or manic BD performs and

1 behaves similarly as SCZ; and oppositely, depressive BD is always misdiagnosed as MDD,
2 resulting in limited therapeutic effects. Additionally, the second-generation antipsychotics play an
3 important role in treatment of BD, SCZ and MDD, indicating potential shared biological
4 mechanism among these phenotypes. Linkage disequilibrium (LD) score analysis indicated that
5 BDI is much more genetically correlated with SCZ, whereas the genetic correlation of BDII with
6 MDD is higher¹¹. These provide a new perspective into genetic correlation between BDI , BDII,
7 SCZ and MDD. Moreover, molecular genetic studies have uncovered overlapped risk factors
8 between genomic architecture of psychiatric disorders^{6, 11, 12, 15}; however, current diagnostic
9 systems failed to elucidate it clearly.

10 To better understand BD etiology and taxonomy, here our study aimed to provide more evidence
11 through post-GWAS analyses. Integrative Omics approaches were adopted to navigate functional
12 genes expressed in the influenced brain regions. Additionally, we explored cross-phenotype
13 genetic structure in adult psychiatric disorders. We are challenging to enrich the research domain
14 criteria (RDoC), re-evaluate and provide new evidence for the cross-disease diagnosis of mental
15 disorders.

16

17

1 **Methods and Materials**

2 **Study Design and GWAS data resources**

3 The genome-wide association (GWA) meta-analysis summary data of BDI and II were from the
4 Psychiatric Genomics Consortium Bipolar Disorder Working Group (PGC3 BD), containing BDI
5 (25,060 cases and 449,978 controls) and BDII (6,781 cases, 364,075 controls), respectively. All
6 participants are European descents, and diagnosis is explicitly based on international consensus
7 criteria (DSM-IV, ICD-9 or ICD-10). Details on participant and cohort information, quality
8 control can be accessed¹¹. Nominal significant instrumental variants (IVs) of response to lithium
9 salt in bipolar disorder¹⁷⁻¹⁹ were downloaded from National Human Genome Research Institute–
10 European Bioinformatics Institute (NHGRI-EBI) GWAS Catalog²⁰ (<https://www.ebi.ac.uk/>). The
11 latest and biggest GWA meta-analysis summary statistics for SCZ (69,369 cases;
12 236,642controls)²¹, and MDD except samples in 23andMe dataset (59,851 cases and 113,154
13 controls)²² were also downloaded from PGC website. Overall post-GWAS analysis pipeline is
14 shown in Figure 1.

16 **Single-marker Analysis**

17 ***PleioFDR analysis***

18 For genetic overlap, we used pleiotropy-informed conditional false discovery rate (pleioFDR)
19 methods²³, including conditional FDR (condFDR), an extension of the standard FDR, and
20 conjunctive FDR (conjFDR) analysis, defined in turn as the maximum of the two condFDR
21 values. The pleioFDR provided a conservative estimate of the FDR associated
22 with both phenotypes, and was applied to identify specific shared loci. Based on an empirical

Bayesian statistical framework, this statistical framework increased statistical power in detecting SNPs that did not reach genome-wide significance. Independent significant SNPs was defined with $\text{condFDR} < 0.01$.

CC-GWAS analysis

For genetic uniqueness, we applied CC-GWAS method²⁴. CC-GWAS perceives differences in minor allele frequencies (MAF) across two traits by analyzing case-control GWAS summary statistics for each other. It weighted the effect size using two methods, ordinary least squares (OLS) weights and Exact weights. To effectively control an increased type I error rate caused by suspect null-null SNPs, SNPs with $p_{\text{OLS}} < 5 \times 10^{-8}$ were remained. Then those failed to pass the required level of significance of CC-GWAS ($p_{\text{EXACT}} > 1 \times 10^{-4}$) were excluded to avoid type I error rate caused by suspect stress test SNPs.

Multi-marker Analysis

Gene-based analysis

Independent genomic loci were mapped by shared and trait-specific SNPs from GWAS summary data of BD I, BD II and CC-GWAS results using ANNOVAR employed in Functional Mapping and Annotation of GWAS (FUMA)²⁵ online platform (<https://fuma.ctglab.nl/>). Significant SNPs were firstly selected by LD $r^2 \geq 0.6$ within a 10kb windows. Second, we narrowed lead SNPs with LD $r^2 \geq 0.1$ with the same window. Genomic risk loci were identified by merging lead SNPs if they were closer than 250 kb, thus containing multiple lead SNPs. The European samples retrieved from the phase 3 of the 1000 Genomes Project (1000G EUR)²⁶ was used to calculate LD.

1 To further define independent genomic loci diverged in BDI & II, we utilized MAGMA v1.6
2 implemented in FUMA²⁵. Gene locations and boundaries were from the NCBI Build GRCh37
3 assembly. A locus that was not reported by original GWAS or GWAS Catalog was considered as
4 novel.

5

6 ***Pathway-based annotation***

7 Functional annotation was performed to uncover the likely biological mechanisms linking and
8 distinguishing BDI & II. Enrichment for the genes mapped to all (candidate and lead) SNPs and
9 genes nearest to lead SNPs in the identified shared loci was evaluated by the Molecular Signatures
10 Database (MsigdB) via a hypergeometric test implemented in FUMA²⁵. Genes without unique
11 entrez ID were excluded. Pathway containing less than 2 genes was removed. The results were
12 adjusted by Benjamini-Hochberg false discovery rate (BH FDR) of 0.05.

13

14 **Integrative genomic-transcriptomic analysis**

15 ***Integrative expression quantitative trait locus (eQTL) analysis***

16 To detect important but non-genome-wide significant sites, we firstly used summary-data-based
17 Mendelian randomization (SMR)²⁷ to estimate loci with strong evidence of causal effects of
18 brain²⁸⁻³¹ and blood³² via gene expression in BDI and BDII risk. SMR analysis was limited to
19 significant cis eQTL ($p_{\text{eQTL}} < 5 \times 10^{-8}$), with minor allele frequency (MAF) > 0.20, and passing
20 Heterogeneity In Dependent Instruments outlier (HEIDI-outlier) test ($p \geq 0.01$) due to its
21 conservativeness^{27,33}. Significant loci were filtered after multiple testing and within 1MB distance
22 from each probe.

1

2 ***Brain region-specific eQTL annotation***

3 Likewise, we conducted brain-specific analyses using e-MAGMA³⁴ and FUSION³⁵, a
4 transcriptome-wide association study (TWAS) to map genes based on precomputed tissue-specific
5 eQTL statistics leveraging 13 brain tissues of GTEx v8³⁶ and test whether SNPs influencing gene
6 expression are also associated with BDI & II. The 1000G EUR were used as reference dataset to
7 account for LD between SNPs. FDR correction were also applied to control the multiple tests
8 performed on the numbers of genes in each process.

9

10 **Cross-phenotype analysis**

11 ***BDI & II versus lithium treatment responses***

12 We then investigate bi-directional causal relationships between BDI & II and lithium salt response
13 using the “TwoSampleMR” (Version 0.5.3) and “MendelianRandomization” (Version 0.5.1) R
14 packages. We selected independent SNPs with P-value $< 5 \times 10^{-6}$ and harmonized exposure and
15 outcome data for both directions. For two sample MR analysis, we used inverse variance
16 weighted (IVW), Weighted median based regression and MR-Egger as the primary method. MR-
17 Egger intercept test and MR pleiotropy residual sum and outlier (MR-PRESSO) test³⁷ were used
18 to evaluate potential IV horizontal pleiotropy.

19

20 ***BDI & II versus major psychiatric diseases***

21 To explore genetic causal associations between BDI, BDII, SCZ, and MDD, we conducted bi-
22 directional MR analysis for four traits to generate hypotheses concerning the direction of

1 causation between each pair of the heritable variables using generalized Summary-data-based
2 Mendelian Randomization (GSMR)³⁸. We denoted x as an exposure trait significantly associated
3 with z (Genetic variants), a putative causal trait for y (the outcome trait) for the same z. The effect
4 of x on y was calculated by two-step least squares approach. The estimate $\hat{b}_{xy}$ and its standard
5 error from multiple Instrumental variants were associated with the exposure trait at a genome-
6 wide significant level ($p < 5 \times 10^{-8}$). Attribute to insufficient instruments included in analyses, a p-
7 value threshold of 5×10^{-5} was used. In GSMR, genetic instruments with pleiotropic effects are
8 detected and eliminated by the HEIDI-outlier procedure, which was the same with SMR. We used
9 default options in GSMR with HEIDI testing for the detection of instrumental outliers ($LD\ r^2 <$
10 0.05, and at least 10 SNPs were required).

11
12 To estimate the genetic correlation between the two bipolar subtypes, SCZ and MDD, we applied
13 MiXeR^{39, 40} as a polygenic overlap analysis. Univariate models estimated polygenicity (estimated
14 number of variants) and discoverability (the average magnitude of additive genetic associations
15 across variants) of each phenotype. Bivariate Gaussian mixture models were also applied to
16 estimate the number of variants influencing each trait that explained 90% of h^2_{snp} and their overlap
17 between each other. MiXeR calculated a Dice coefficient, a ratio of shared variants to the total
18 number of variants, to evaluate the polygenic overlap. In line with Akaike information criterion
19 (AIC), MiXeR evaluated model fitting based on current power of input summary statistics.

20

21

Results

Genetic overlaps between bipolar type I and II

For signals shared by BDI and BDII, the pleioFDR analysis identified 74 significant SNPs ($p < 0.01$) that are mapped to 3 genomic loci (Table 1 and Figure 2A): zinc finger protein 184, *ZNF184*, mapped by *rs67240003* ($p_{\text{FDR}} = 5.26 \times 10^{-3}$), and *ribosomal protein L10a pseudogene 3*, *RPL10AP3*, mapped by *rs6990255* ($p_{\text{FDR}} = 7.54 \times 10^{-3}$). Another one is consistent with the newest BD GWAS: solute carrier family 25 member 17, *SLC25A17*, mapped by *rs5758064* ($p_{\text{FDR}} = 7.47 \times 10^{-3}$). The shared genomic loci, candidate independent SNPs, allelic association and novelty for BD were summarized in Supplementary Table S1. The stratified conditional Quantile-Quantile (Q-Q) plots showed SNP enrichment for BDI condition on association with BDII and vice versa (Supplementary Figure S1), suggesting the existence of polygenic overlap.

Genetic distinction of Bipolar type I and II

CC-GWAS analysis was applied to the publicly available summary statistics for BDI and BDII. The only one CC-GWAS BDI versus BDII SNP was *rs12154473*, located on chromosome 7p22.3 ($p_{\text{OLS}} = 2.83 \times 10^{-8}$; $p_{\text{EXACT}} = 6.07 \times 10^{-5}$; Table 2 and Supplementary Table S2 and S3). The Manhattan plot of CC-GWAS results was shown in Figure 2B. The genetic distance between individuals with BDI and BDII is only slightly smaller (0.55) than the case-control distances for BDI (0.62) and BDII (0.62) (Supplementary Figure S2).

In the gene-based analysis, a total of 18,626 genes were tested among them. Nine genes showed distinction between BDI & II after multiple testing ($p < 0.05/18626 = 2.68 \times 10^{-6}$). The top hit was mitotic arrest deficient 1 like 1, *MADILI1*. Besides, a total of 18,847 or 18,830 genes were tested

by FUMA for BDI, BDII, respectively. After Bonferroni correction, 129 genes were significant for BDI, gene *CACNA1C* ($p = 2.80 \times 10^{-11}$), *MAD1L1* ($p = 7.56 \times 10^{-11}$), the same with CC-GWAS, and *TMEM258* ($p = 9.48 \times 10^{-11}$), are the top three genes of BDI. The only significant gene of BDII is *SLIT3* ($p = 7.92 \times 10^{-9}$). Details of genes significantly associated with each phenotype after correction for multiple testing were shown in Supplementary Table S4.

Pathway analyses were next performed for BDI, CC-GWAS and BDII, respectively. 11, 6 and one pathways were significantly enriched by the genes through MAGMA analysis for BDI, CC-GWAS and BDII GWAS summary statistics ($P_{\text{Bonferroni}} < 0.05$). As for BDI, the “neuron part”, “somatodendritic compartment”, “high voltage gated calcium channel activity” and “voltage gated calcium channel activity involved in cardiac muscle cell action potential” were gene ontology pathways verified by CC-GWAS and BDI. As for BDII, the only significant pathway was the “Hirsch cellular transformation signature up” ($p = 9.84 \times 10^{-5}$). The mapped pathways and genes were in Supplementary Table S5.

TWAS analyses in blood and brain regions

SMR was used to prioritize eQTLs playing causal roles in BDI & II via gene expression in blood and brain. 11 in brain ($p_{\text{SMR}} < 6.61 \times 10^{-6}$) and 49 in blood ($p_{\text{SMR}} < 3.19 \times 10^{-6}$) putative BDI significantly associated genes were identified after multiple testing correction and heterogeneity test. The top loci were NMB and FADS1 for BDI in blood and brain, respectively (Supplementary Figure S3). We did not observe significant results for the smaller sample BDII after multiple testing. The related genomic loci, candidate SNPs and allelic association for BDI were summarized in Supplementary Table S6 and S7.

1

2 TWAS was conducted by e-MAGMA and FUSION in 13 brain regions included in GTEx v8.

3 Expression of genes was influenced by trait-associated sites, respectively. E-MAGMA identified

4 148 loci ($p_{FDR} < 0.05$) of BDI. *FADS1* ($p_{FDR} = 1.87 \times 10^{-7}$), *PLEC* ($p_{FDR} = 3.10 \times 10^{-7}$) and *ITIH4*

5 ($p_{FDR} = 3.10 \times 10^{-7}$) were the top ones. These genes encompassed 3 brain regions, including

6 hypothalamus, amygdala, and cerebellum (Supplementary Table S8). Similarly, FUSION indicated

7 336 genes ($p_{FDR} < 0.05$, 9 hits of previous GWAS of BD achieved nominal significance) of BDI

8 (Supplementary Table S9) among all the 13 brain regions.

9 As for BDII, two genes showed significant association with BDII by e-MAGMA after correction

10 for multiple testing: G protein subunit alpha I 1 on chromosome 7 (*GNAI1*, $p_{FDR} = 2.64 \times 10^{-7}$) and

11 serine protease 16 on chromosome 6 (*PRSSI6*, $p_{FDR} = 1.40 \times 10^{-5}$). Both were over-expressed in

12 cerebellum (Supplementary Table S10). 21 genes were significant by FUSION after multiple tests

13 among brain regions without nucleus accumbens (NAc) (Supplementary Table S11). The top hit

14 was *AC005932.1* ($p_{FDR} = 2.07 \times 10^{-4}$), a novel nominal significant gene for BDII. The located

15 chromosome regions, correlated brain regions and numbers of association with eQTLs were

16 represented in Figure 3 and Supplementary Table S12.

17

18

19 **Correlations between BDI & II and response to lithium**

20 Two-sample Mendelian Randomization analysis suggested there might be an effect estimate

21 consistent with increased risk for response to lithium ion (BDI: Weighted median, $\beta = 1.89$;

22 standard error (SE), 0.426; $p = 9.57 \times 10^{-6}$), while none for BDII (Inverse weighted regression,

1 beta=3.27; SE, 2.28; P = 0.15). Based on different hypothesis, MR-Egger and MRR-PRESSO
2 displayed opposite results. BDI passed MR-Egger intercept analysis (MR-Egger intercept = 0.41;
3 p = 0.10), while did not pass MR-PRESSO ($p_{\text{Global test}} < 0.001$), indicating existence of horizontal
4 pleiotropy (Supplementary Table S13).

5

6 **Genetic overlaps between BDI & II and other traits**

7 Bi-directional MR investigating causal relationships between two BDI & II and traits of interests
8 (SCZ and MDD) was shown in (Supplementary Table S14). GSKMR analyses provided evidence
9 that genetically SCZ provided a 0.50-fold and 0.32-fold causality increase in BDI and BDII,
10 respectively. Inversely, MDD increased causality with BDI, BDII by 0.23-fold and 1.11-fold,
11 respectively. In the other direction, BDI provided 0.32-fold causal effect on SCZ (beta=0.32, SE=
12 0.019, $p=3.70 \times 10^{-62}$), comparing with less effect on MDD (beta=0.043, SE= 0.018, $p=1.36 \times 10^{-2}$).
13 Since the number of SNPs ought to be over 10, p-value threshold was set to be 5×10^{-5} when BDII
14 was computed into clumping as exposure trait. The causal relationship between BDII and SCZ
15 (beta=0.073, SE= 0.008, $p= 1.12 \times 10^{-21}$), were very close to BDII and MDD (beta=0.050, SE=
16 0.008, $p= 7.71 \times 10^{-11}$). BDI and BDII are presented with causality with each other
17 (Supplementary Table S14)

18 MiXeR estimated that approximately 7.88 k (SE = 0.26 k) variants influence BDI, which was
19 comparable to the case of SCZ (9.82 k; SE= 0.22 k), lower than that for major depression (21.6 k,
20 SE = 2.64 k) and 19.82 k (SE = 21.12 k) variants influenced BDII. Deficiency of sample size may
21 explain the odd statistics in BDII. MiXeR also revealed a higher polygenicity in BDII and MDD
22 than BDI and SCZ. In BDI and BDII, 7.47 k (SE = 0.29k) and 7.47 k (SE = 1.73k) variants were

1 associated with SCZ, and 5.44 k (SE = 0.59k) and 13.23 k (SE = 5.91k) variants were associated
 2 with MDD, respectively. Consistent with LD score regression, MiXeR showed that BDI enjoyed
 3 higher genetic correlation with SCZ ($r_g = 0.70$) than MDD ($r_g = 0.39$), and oppositely, BDII
 4 possessed higher genetic correlation with MDD ($r_g = 0.68$) than SCZ ($r_g = 0.61$) (Supplementary
 5 Figure S4 and Table S15).

6

1 Discussion

2 The present study is the first comprehensive post-GWAS analysis of BDI & II with latest and
 3 largest PGC dataset on bipolar disorder. Different from the original study that aimed to identify
 4 novel genes and drug targets using overall BD as primary phenotype¹¹, our integrative genomic
 5 analyses answered directly to the question remained: what are the shared and distinct genetic
 6 components of BD subtypes? Our secondary analyses of the existing dataset focus on the
 7 unanswered question in Mullins et al.'s study and generate complementary findings (e.g., novel
 8 genes and gene-sets). In this study, we corroborated and expanded evidence from previous
 9 clinical and genetic studies that there did exist a partially shared genetic basis between BDI & II
 10 and provided further insights into their genetic divergence. When compared to other earlier studies
 11 on the same research question (Table S16), our study is innovative from different aspects: 1) larger
 12 sample size for both BD I and BD II; 2) more systematic statistical genetics analyses; 3) new
 13 biological explanation to the distinction of BD subtypes.

14
 15 For genetic convergence, three loci were identified shared by BDI & II: *SLC25A17*, *ZNF184* and
 16 *RPL10AP3*. All of these loci were previously reported to be associated with bipolar disorder,
 17 depression, ADHD, autism spectrum disorder, or schizophrenia⁴¹⁻⁴⁴, underpinning their
 18 contribution to mental disorder risk. *ZNF184* has been reported to be likely associated with
 19 subcortical volume⁴⁵, despite the unclear biological function in neurodevelopment. Research for
 20 links between mental and physical disorders is also proposed^{41, 46-48}

21

1 For genetic divergence, notably, *MAD1L1* that was reported to be genome-wide significant in the
2 two previous BD GWAS^{49, 50} including Asian samples, achieved nominal significance
3 distinguishing BDI & II in this study. This gene contributes to cell cycle control through the
4 regulation of mitosis, and has been shown having pleiotropic effect on psychosis and BD before^{15,}
5 ^{51, 52}. Our study suggests that *MAD1L1* may be a genetic marker of BDI, promoting further
6 biological research on it. Moreover, *MRM1*, *ZNHIT3*, *DHRS11*, *GGNBP2* are firstly reported
7 significant in the gene-based test. *SLIT3* was identified to be BDII-specific by gene-based analysis.
8 *SLIT3* has been shown to play a critical role in the formation and maintenance of the nervous
9 system⁵³, SCZ⁵⁴, treatment resistant depression⁵⁵ and alcohol dependence⁵⁶, indicating generally
10 shared genetic association among psychiatric disorders.

11

12 Enriched gene-sets of BDI were involved in neuronal and postsynaptic compartments, as well as
13 calcium channel activity, triggering presynaptic signaling, which reconfirmed cross-phenotype
14 correlation across BD, SCZ, ASD and cognitive deficiency^{16, 57-59}. These pathway processes may
15 indicate BDI primarily represents BD biological features and point deeper research into common
16 biological pathogenesis among mental disorders. As a comparison, the BDII-specific pathway
17 effects generally link with cancer, inflammatory and metabolic diseases⁶⁰, hence suggesting larger
18 cohorts are required to provide mechanistic prompt for further research into BDII.

19

20 Interestingly, from the integrative Omics analysis, we found *FADS1* as the one of the three top
21 eQTL-associated loci shared by both brain and blood, is presented with opposite directions of
22 effect on gene expression in the two different tissues. This observation also suggests *FADS1*

possibly plays a role in the tissue-specific gene regulation of BDI. The possible reason was that *FADS1* is strongly associated with blood cell and lipid and glucose metabolite⁶¹⁻⁶⁴, and thus highly expressed in blood. Brain region-specific eQTL analysis yielded 15 genes specific for BDII. These eQTLs provide promising candidate genes for subsequent functional experiments, especially *NOS2* (Nitric oxide synthase 2) and *CASP8* (Caspase-8), participate in drug metabolism⁶⁵, despite no correlation to psychosis was yet found. While several of these genes are implicated by genome-wide significant loci, many of them are not the closest gene to the index SNP, highlighting the value of probing underlying molecular mechanisms to prioritize the most likely causal genes in each corresponding locus and moving from genes to functional mechanism.

In addition, the results of this study also suggest that BDI and BDII significantly differ in biosignatures as revealed by gene expression differentiation in functional brain regions and drug response. Gene expression differentiation in NAc might represent an endophenotype of BDI addressing dysfunction of brain circuits. By regulating dopamine release and midbrain dopamine system, NAc contributes to onset of SCZ^{66, 67}, especially for delusion and hallucination. It is also a contributor to the pathophysiology of BD, as shown from a postmortem brain analysis⁶⁸. Even though we did not find direct causal relationships between BDI, II and lithium ion, there indeed exists a linkage with lithium response following the guidelines⁶⁹: lithium was first-line to BDI, but not to BDII. Lithium is more effective for patients sharing etiological homogeneity; based on longitudinal stability and familial clustering, lithium response has been suggested to define a distinct genetically based BD nosology¹⁹. Therefore, biological indicators like treatment response, clinical prognosis and progression of BDI and BDII should be included in genetic analysis, and

1 enable to improve precise clinical decision making. It's also the RDoC standard that combination
2 of neuroscience research will be helpful for future genetic research, even alter clinical
3 management⁷⁰.

4
5 Another interesting finding of this study is the polygenicity and causality of BDI & II with other
6 psychiatric disorders irrespective of genetic correlation^{39, 40}. BDI and BDII apparently associated
7 with each other according to the bidirectional causal associations from GSMR and mixed
8 directional overlap from MiXeR in spite that it is confusing to explain whether the causal
9 relationships driven by other covariates³⁸. Meanwhile, MiXeR analysis prompted a higher
10 clinical heterogeneity for BDII-MDD pair, when compared with BDI-SCZ pair. Stronger genetic
11 correlation with SCZ inheres in BDI, while a strong association with MDD was seen in BDII.
12 Despite inadequate sample size, consistent results were found from GSMR analysis.

13
14 According to our focalization , relationships among these disorders could be that they share
15 continuous genetic structures⁷¹. BD subtypes may help fill the gap across mental disorders by
16 revealing transdiagnostic biotypes. Insights into such genetic structure may greatly contribute to
17 clinical decision-making in prophylaxis or management of the disorder. This pattern also strongly
18 supports psychiatric disorders could not be regarded as completely independent disease entities.
19 The findings of this study will also trigger larger studies on BDII and other biotypes like psychosis
20 bipolar disorder and cyclothymia, because current BD GWAS mainly reflected the genetic
21 characteristics of BDI, the majority of overall BD cases. Although a large sample size of GWAS is
22 always important in nowadays genomic studies, the statistical power will be greatly reduced when

1 there is nonnegligible clinical heterogeneity caused by the classification system within disease
 2 phenotype⁷². Therefore, as RDoC emphasized, large-scale transdiagnostic investigations are
 3 urgently needed to untangle whether impairment or symptoms can be regarded subtype-specific,
 4 and so do multi-omics analysis⁷³.

5
 6 One of the potential limitations of our study is that the population imbalance of BDII GWAS
 7 summary statistics may be susceptible to bias. We were restricted to find more loci in each level of
 8 our study compared with its relatively higher heritability to MDD. Further collection and analysis
 9 should be emphasized on BDII. Another limitation is that we failed to achieve individual
 10 genotypes, leading to the incompleteness of some important analyses, such as polygenic risk score
 11 (PRS) calculation, and so on. Finally, our study only obtained GWAS summary statistics of BDI
 12 and BDII, lacking data from other BD subtypes.

13
 14 In summary, genetic evidence deepens our understanding of the biological etiology of BD and
 15 prioritizes a set of candidate genes distinguishing BDI & II for functional follow-up experiments
 16 and indicates a spectrum connecting psychiatric disorders, which enable better ways to optimize
 17 nosology and precise treatments in psychiatry.

18

19

1 **Acknowledgments**

2 This study was financially supported by the National Nature Science Foundation of China (Grant
3 NO.81771446 to QW, NO.82171499 to QW and 82071524 to ML), Science and Technology
4 Project of Sichuan Province (2021YJ0238 to ML). HG is supported by Mentored Scientist Grant
5 in Henry Ford Hospital.

6

7 **Conflict of Interest**

8 All authors declare that they have no conflict of interest.

9

Reference

1. Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA *et al.* Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. *Arch Gen Psychiatry* 2011; **68**(3): 241-251.
2. Huang Y, Wang Y, Wang H, Liu Z, Yu X, Yan J *et al.* Prevalence of mental disorders in China: a cross-sectional epidemiological study. *Lancet Psychiatry* 2019; **6**(3): 211-224.
3. Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; **392**(10159): 1789-1858.
4. Bienvenu OJ, Davydow DS, Kendler KS. Psychiatric 'diseases' versus behavioral disorders and degree of genetic influence. *Psychol Med* 2011; **41**(1): 33-40.
5. Edvardsen J, Torgersen S, Roysamb E, Lygren S, Skre I, Onstad S *et al.* Heritability of bipolar spectrum disorders. Unity or heterogeneity? *J Affect Disord* 2008; **106**(3): 229-240.
6. Stahl EA, Breen G, Forstner AJ, McQuillin A, Ripke S, Trubetskoy V *et al.* Genome-

- 1 wide association study identifies 30 loci associated with bipolar disorder. *Nat Genet*
- 2 2019; **51**(5): 793-803.
- 3
- 4 7. Li HJ, Zhang C, Hui L, Zhou DS, Li Y, Zhang CY *et al.* Novel Risk Loci Associated
- 5 With Genetic Risk for Bipolar Disorder Among Han Chinese Individuals: A Genome-
- 6 Wide Association Study and Meta-analysis. *JAMA Psychiatry* 2021; **78**(3): 320-330.
- 7
- 8 8. American Psychiatric Association Diagnostic and Statistical Manual of Mental
- 9 Disorders 5th edn ((American Psychiatric Association Publishing, 2013).
- 10
- 11 9. Kieseppa T, Partonen T, Haukka J, Kaprio J, Lonnqvist J. High concordance of
- 12 bipolar I disorder in a nationwide sample of twins. *Am J Psychiatry* 2004; **161**(10):
- 13 1814-1821.
- 14
- 15 10. Bertelsen A, Harvald B, Hauge M. A Danish twin study of manic-depressive disorders.
- 16 *Br J Psychiatry* 1977; **130**: 330-351.
- 17
- 18 11. Mullins N, Forstner AJ, O'Connell KS, Coombes B, Coleman JRI, Qiao Z *et al.*
- 19 Genome-wide association study of more than 40,000 bipolar disorder cases provides
- 20 new insights into the underlying biology. *Nat Genet* 2021; **53**(6): 817-829.
- 21
- 22 12. Psychiatric GCB DWG. Large-scale genome-wide association analysis of bipolar

- 1 disorder identifies a new susceptibility locus near ODZ4. *Nat Genet* 2011; **43**(10):
- 2 977-983.
- 3
- 4 13. Bebbington P, Ramana R. The epidemiology of bipolar affective disorder. *Soc*
- 5 *Psychiatry Psychiatr Epidemiol* 1995; **30**(6): 279-292.
- 6
- 7 14. Judd LL, Schettler PJ, Solomon DA, Maser JD, Coryell W, Endicott J *et al.*
- 8 Psychosocial disability and work role function compared across the long-term course
- 9 of bipolar I, bipolar II and unipolar major depressive disorders. *J Affect Disord* 2008;
- 10 **108**(1-2): 49-58.
- 11
- 12 15. Charney AW, Ruderfer DM, Stahl EA, Moran JL, Chambert K, Belliveau RA *et al.*
- 13 Evidence for genetic heterogeneity between clinical subtypes of bipolar disorder.
- 14 *Transl Psychiatry* 2017; **7**(1): e993.
- 15
- 16 16. Bipolar D, Schizophrenia Working Group of the Psychiatric Genomics Consortium.
- 17 Electronic address drive, Bipolar D, Schizophrenia Working Group of the Psychiatric
- 18 Genomics C. Genomic Dissection of Bipolar Disorder and Schizophrenia, Including
- 19 28 Subphenotypes. *Cell* 2018; **173**(7): 1705-1715 e1716.
- 20
- 21 17. Song J, Bergen SE, Di Florio A, Karlsson R, Charney A, Ruderfer DM *et al.* Genome-
- 22 wide association study identifies SESTD1 as a novel risk gene for lithium-responsive

- 1 bipolar disorder. *Mol Psychiatry* 2016; **21**(9): 1290-1297.
- 2
- 3 18. Hou L, Heilbronner U, Degenhardt F, Adli M, Akiyama K, Akula N *et al*. Genetic
- 4 variants associated with response to lithium treatment in bipolar disorder: a genome-
- 5 wide association study. *Lancet* 2016; **387**(10023): 1085-1093.
- 6
- 7 19. International Consortium on Lithium G, Amare AT, Schubert KO, Hou L, Clark SR,
- 8 Papiol S *et al*. Association of Polygenic Score for Schizophrenia and HLA Antigen
- 9 and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder: A
- 10 Genome-Wide Association Study. *JAMA Psychiatry* 2018; **75**(1): 65-74.
- 11
- 12 20. Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C *et al*. The
- 13 NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted
- 14 arrays and summary statistics 2019. *Nucleic Acids Res* 2019; **47**(D1): D1005-D1012.
- 15
- 16 21. Ripke S, Walters JTR, O'Donovan MC. 2020.
- 17
- 18 22. Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A *et al*.
- 19 Genome-wide association analyses identify 44 risk variants and refine the genetic
- 20 architecture of major depression. *Nat Genet* 2018; **50**(5): 668-681.
- 21
- 22 23. Andreassen OA, Thompson WK, Schork AJ, Ripke S, Mattingsdal M, Kelsoe JR *et al*.

1 Improved detection of common variants associated with schizophrenia and bipolar
2 disorder using pleiotropy-informed conditional false discovery rate. *PLoS Genet* 2013;
3 9(4): e1003455.
4
5 24. Peyrot WJ, Price AL. Identifying loci with different allele frequencies among cases of
6 eight psychiatric disorders using CC-GWAS. *Nat Genet* 2021; 53(4): 445-454.
7
8 25. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and
9 annotation of genetic associations with FUMA. *Nat Commun* 2017; 8(1): 1826.
10
11 26. Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM *et al.* A
12 global reference for human genetic variation. *Nature* 2015; 526(7571): 68-74.
13
14 27. Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE *et al.* Integration of
15 summary data from GWAS and eQTL studies predicts complex trait gene targets. *Nat*
16 *Genet* 2016; 48(5): 481-487.
17
18 28. Qi T, Wu Y, Zeng J, Zhang F, Xue A, Jiang L *et al.* Identifying gene targets for brain-
19 related traits using transcriptomic and methylomic data from blood. *Nat Commun*
20 2018; 9(1): 2282.
21
22 29. Consortium GT, Laboratory DA, Coordinating Center -Analysis Working G, Statistical

1 Methods groups-Analysis Working G, Enhancing Gg, Fund NIHC *et al.* Genetic
2 effects on gene expression across human tissues. *Nature* 2017; **550**(7675): 204-213.
3
4 30. Fromer M, Roussos P, Sieberts SK, Johnson JS, Kavanagh DH, Perumal TM *et al.*
5 Gene expression elucidates functional impact of polygenic risk for schizophrenia. *Nat*
6 *Neurosci* 2016; **19**(11): 1442-1453.
7
8 31. Ng B, White CC, Klein HU, Sieberts SK, McCabe C, Patrick E *et al.* An xQTL map
9 integrates the genetic architecture of the human brain's transcriptome and epigenome.
10 *Nat Neurosci* 2017; **20**(10): 1418-1426.
11
12 32. Vosa U, Claringbould A, Westra HJ, Bonder MJ, Deelen P, Zeng B *et al.* Large-scale
13 cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores
14 that regulate blood gene expression. *Nat Genet* 2021; **53**(9): 1300-1310.
15
16 33. Zhu Z, Zheng Z, Zhang F, Wu Y, Trzaskowski M, Maier R *et al.* Causal associations
17 between risk factors and common diseases inferred from GWAS summary data. *Nat*
18 *Commun* 2018; **9**(1): 224.
19
20 34. Gerring ZF, Mina-Vargas A, Gamazon ER, Derks EM. E-MAGMA: an eQTL-informed
21 method to identify risk genes using genome-wide association study summary
22 statistics. *Bioinformatics* 2021.

1

2 35. Gusev A, Ko A, Shi H, Bhatia G, Chung W, Penninx BW *et al.* Integrative approaches
3 for large-scale transcriptome-wide association studies. *Nat Genet* 2016; **48**(3): 245-
4 252.

5

6 36. Consortium GT. The GTEx Consortium atlas of genetic regulatory effects across
7 human tissues. *Science* 2020; **369**(6509): 1318-1330.

8

9 37. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy
10 in causal relationships inferred from Mendelian randomization between complex traits
11 and diseases. *Nat Genet* 2018; **50**(5): 693-698.

12

13 38. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex
14 trait analysis. *Am J Hum Genet* 2011; **88**(1): 76-82.

15

16 39. Frei O, Holland D, Smeland OB, Shadrin AA, Fan CC, Maeland S *et al.* Bivariate
17 causal mixture model quantifies polygenic overlap between complex traits beyond
18 genetic correlation. *Nat Commun* 2019; **10**(1): 2417.

19

20 40. Holland D, Frei O, Desikan R, Fan CC, Shadrin AA, Smeland OB *et al.* Beyond SNP
21 heritability: Polygenicity and discoverability of phenotypes estimated with a univariate
22 Gaussian mixture model. *PLoS Genet* 2020; **16**(5): e1008612.

- 1
- 2 41. Ferguson A, Lyall LM, Ward J, Strawbridge RJ, Cullen B, Graham N *et al.* Genome-
- 3 Wide Association Study of Circadian Rhythmicity in 71,500 UK Biobank Participants
- 4 and Polygenic Association with Mood Instability. *EBioMedicine* 2018; **35**: 279-287.
- 5
- 6 42. Autism Spectrum Disorders Working Group of The Psychiatric Genomics C. Meta-
- 7 analysis of GWAS of over 16,000 individuals with autism spectrum disorder highlights
- 8 a novel locus at 10q24.32 and a significant overlap with schizophrenia. *Mol Autism*
- 9 2017; **8**: 21.
- 10
- 11 43. Wu Y, Cao H, Baranova A, Huang H, Li S, Cai L *et al.* Multi-trait analysis for genome-
- 12 wide association study of five psychiatric disorders. *Transl Psychiatry* 2020; **10**(1):
- 13 209.
- 14
- 15 44. Cross-Disorder Group of the Psychiatric Genomics C. Identification of risk loci with
- 16 shared effects on five major psychiatric disorders: a genome-wide analysis. *Lancet*
- 17 2013; **381**(9875): 1371-1379.
- 18
- 19 45. van der Meer D, Frei O, Kaufmann T, Shadrin AA, Devor A, Smeland OB *et al.*
- 20 Understanding the genetic determinants of the brain with MOSTest. *Nat Commun*
- 21 2020; **11**(1): 3512.
- 22

- 1 46. Van Veldhoven PP. Biochemistry and genetics of inherited disorders of peroxisomal
2 fatty acid metabolism. *J Lipid Res* 2010; **51**(10): 2863-2895.
3
4 47. Liu DJ, Peloso GM, Yu H, Butterworth AS, Wang X, Mahajan A *et al.* Exome-wide
5 association study of plasma lipids in >300,000 individuals. *Nat Genet* 2017; **49**(12):
6 1758-1766.
7
8 48. Wain LV, Shrine N, Artigas MS, Erzurumluoglu AM, Noyvert B, Bossini-Castillo L *et al.*
9 Genome-wide association analyses for lung function and chronic obstructive
10 pulmonary disease identify new loci and potential druggable targets. *Nat Genet* 2017;
11 **49**(3): 416-425.
12
13 49. Hou L, Bergen SE, Akula N, Song J, Hultman CM, Landen M *et al.* Genome-wide
14 association study of 40,000 individuals identifies two novel loci associated with
15 bipolar disorder. *Hum Mol Genet* 2016; **25**(15): 3383-3394.
16
17 50. Ikeda M, Takahashi A, Kamatani Y, Okahisa Y, Kunugi H, Mori N *et al.* A genome-
18 wide association study identifies two novel susceptibility loci and trans population
19 polygenicity associated with bipolar disorder. *Mol Psychiatry* 2018; **23**(3): 639-647.
20
21 51. Ruderfer DM, Fanous AH, Ripke S, McQuillin A, Amdur RL, Schizophrenia Working
22 Group of the Psychiatric Genomics C *et al.* Polygenic dissection of diagnosis and

1 clinical dimensions of bipolar disorder and schizophrenia. *Mol Psychiatry*2014; **19**(9):
2 1017-1024.
3
4 52. Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from
5 108 schizophrenia-associated genetic loci. *Nature* 2014; **511**(7510): 421-427.
6
7 53. Vargesson N, Luria V, Messina I, Erskine L, Laufer E. Expression patterns of Slit and
8 Robo family members during vertebrate limb development. *Mech Dev*2001; **106**(1-2):
9 175-180.
10
11 54. Shi Y, Zhao X, Yu L, Tao R, Tang J, La Y *et al*. Genetic structure adds power to
12 detect schizophrenia susceptibility at SLIT3 in the Chinese Han population. *Genome*
13 *Res*2004; **14**(7): 1345-1349.
14
15 55. Fabbri C, Kasper S, Kautzky A, Bartova L, Dold M, Zohar J *et al*. Genome-wide
16 association study of treatment-resistance in depression and meta-analysis of three
17 independent samples. *Br J Psychiatry*2019; **214**(1): 36-41.
18
19 56. Chen G, Zhang F, Xue W, Wu R, Xu H, Wang K *et al*. An association study revealed
20 substantial effects of dominance, epistasis and substance dependence co-morbidity
21 on alcohol dependence symptom count. *Addict Biol*2017; **22**(6): 1475-1485.
22

- 1 57. Forstner AJ, Hecker J, Hofmann A, Maaser A, Reinbold CS, Muhleisen TW *et al.*
2 Identification of shared risk loci and pathways for bipolar disorder and schizophrenia.
3 *PLoS One* 2017; **12**(2): e0171595.
4
5 58. Cupertino RB, Kappel DB, Bandeira CE, Schuch JB, da Silva BS, Muller D *et al.*
6 SNARE complex in developmental psychiatry: neurotransmitter exocytosis and
7 beyond. *J Neural Transm (Vienna)* 2016; **123**(8): 867-883.
8
9 59. Pescosolido MF, Gamsiz ED, Nagpal S, Morrow EM. Distribution of disease-
10 associated copy number variants across distinct disorders of cognitive development.
11 *J Am Acad Child Adolesc Psychiatry* 2013; **52**(4): 414-430 e414.
12
13 60. Hirsch HA, Iliopoulos D, Joshi A, Zhang Y, Jaeger SA, Bulyk M *et al.* A transcriptional
14 signature and common gene networks link cancer with lipid metabolism and diverse
15 human diseases. *Cancer Cell* 2010; **17**(4): 348-361.
16
17 61. Chen HY, Cairns BJ, Small AM, Burr HA, Ambikkumar A, Martinsson A *et al.*
18 Association of FADS1/2 Locus Variants and Polyunsaturated Fatty Acids With Aortic
19 Stenosis. *JAMA Cardiol* 2020; **5**(6): 694-702.
20
21 62. Sabatti C, Service SK, Hartikainen AL, Pouta A, Ripatti S, Brodsky J *et al.* Genome-
22 wide association analysis of metabolic traits in a birth cohort from a founder

- 1 population. *Nat Genet* 2009; **41**(1): 35-46.
- 2
- 3 63. Tabassum R, Ramo JT, Ripatti P, Koskela JT, Kurki M, Karjalainen J *et al.* Genetic
- 4 architecture of human plasma lipidome and its link to cardiovascular disease. *Nat*
- 5 *Commun* 2019; **10**(1): 4329.
- 6
- 7 64. Tintle NL, Pottala JV, Lacey S, Ramachandran V, Westra J, Rogers A *et al.* A
- 8 genome-wide association study of saturated, mono- and polyunsaturated red blood
- 9 cell fatty acids in the Framingham Heart Offspring Study. *Prostaglandins Leukot*
- 10 *Essent Fatty Acids* 2015; **94**: 65-72.
- 11
- 12 65. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF *et al.*
- 13 Pharmacogenomics knowledge for personalized medicine. *Clin Pharmacol Ther* 2012;
- 14 **92**(4): 414-417.
- 15
- 16 66. Eastwood SL, Burnet PW, Harrison PJ. Decreased hippocampal expression of the
- 17 susceptibility gene PPP3CC and other calcineurin subunits in schizophrenia. *Biol*
- 18 *Psychiatry* 2005; **57**(7): 702-710.
- 19
- 20 67. Kozlovsky N, Scarr E, Dean B, Agam G. Postmortem brain calcineurin protein levels
- 21 in schizophrenia patients are not different from controls. *Schizophr Res* 2006; **83**(2-3):
- 22 173-177.

- 1
- 2 68. Kunii Y, Hino M, Matsumoto J, Nagaoka A, Nawa H, Kakita A *et al*. Differential protein
- 3 expression of DARPP-32 versus Calcineurin in the prefrontal cortex and nucleus
- 4 accumbens in schizophrenia and bipolar disorder. *Sci Rep* 2019; **9**(1): 14877.
- 5
- 6 69. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN *et al*. Canadian
- 7 Network for Mood and Anxiety Treatments (CANMAT) and International Society for
- 8 Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar
- 9 disorder. *Bipolar Disord* 2018; **20**(2): 97-170.
- 10
- 11 70. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K *et al*. Research domain
- 12 criteria (RDoC): toward a new classification framework for research on mental
- 13 disorders. *Am J Psychiatry* 2010; **167**(7): 748-751.
- 14
- 15 71. Cross-Disorder Group of the Psychiatric Genomics Consortium. Electronic address
- 16 pmhe, Cross-Disorder Group of the Psychiatric Genomics C. Genomic Relationships,
- 17 Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. *Cell*
- 18 2019; **179**(7): 1469-1482 e1411.
- 19
- 20 72. Mitchell BL, Thorp JG, Wu Y, Campos AI, Nyholt DR, Gordon SD *et al*. Polygenic
- 21 Risk Scores Derived From Varying Definitions of Depression and Risk of Depression.
- 22 *JAMA Psychiatry* 2021.

1

2 73. Cuthbert BN. The role of RDoC in future classification of mental disorders. *Dialogues*

3 *Clin Neurosci* 2020; **22**(1): 81-85.

4

5

6

Figure Legend

Figure 1. Workflow of key methodological steps in this study. PGC: psychiatric genomics consortium, BDI: bipolar disorder type I, BDII: bipolar disorder type II, SCZ: schizophrenia, MDD: major depression disorder.

Figure 2. Manhattan plots showing the association statistics for single marker analysis of BD I & II genetic overlap (Figure 2A) and distinctness (Figure 2B). The y-axis shows the GWAS - $\log_{10}$ P-values per SNP across chromosomes 1-22. **A)** represents SNPs with conditional P-value $< 1 \times 10^{-2}$ are shown with large black points. **B)** represents SNPs identified by case-case genome-wide association analysis (CC-GWAS) with $p < 5 \times 10^{-8}$. The figures show the localization of significant loci. Details about the loci are provided in **Table 1** and **Table 2**.

Figure 3. Shared and trait-specific eQTLs of BD I and BD II. **A)** Genomic regions that are specific to BD I (blue points), specific to BD II (green points), and shared (red points). **B)** Associated 13 brain regions with BDI and BDII: cortex, frontal cortex, anterior cingulate cortex, caudate, putamen, hypothalamus, amygdala, hippocampus, substantia nigra, cerebellum, cerebellar hemisphere and spinal cord cervical c-1 (orange area) and BDI specific brain region: nucleus accumbens (light blue area) **C)** Prioritized genes for shared and trait-specific regions. Genes presented reached significance (after FDR correction) in the TWAS test and were identified by two methods (FUSION and e-MAGMA). The numbers represent trait-specific genes identified by at least one method. Details are in Supplementary Table S8-12

1 Table Legend

2 **Table 1. Conjunction FDR; pleiotropic loci in BD type I (BD I) and BD type II (BD II)**
3 **(BDI&BDII) at conjFDR < 0.01.** Independent complex or single gene loci ($r^2 < 0.2$) with SNP(s)
4 with a conjFDR (conjFDR) < 0.05 in (BDI) and (BDII). All SNPs with a conjFDR
5 value, 0.05 (bidirectional association) and association with BDI & BDII are listed and sorted in
6 each LD block. We defined the most significant SNP in each LD block based on the minimum
7 conjFDR. Chromosome (CHR), minor allele (A1) and major allele (A2), Z-scores for each
8 pleiotropic locus are provided. All data were first corrected for genomic inflation. Locus name is
9 based on exonic lead SNPs. Remaining locus name is based on the nearest gene and do not refer to
10 any inferred biological function. Details are in Supplementary Table S1.

11 * Same locus identified in previous BD genome-wide association studies

12
13 **Table 2. Summary of CC-GWAS results for BDI&BDII.** For the CC-GWAS-specific locus, the
14 lead CC-GWAS SNP and its chromosome, physical position, the locus name, the respective case–
15 control effect sizes and P values and the CC-GWAS OLS and Exact case–case effect size, standard
16 error(se) and P values. Details are in Supplementary Table S3.

A)

B)

A)

B)

C)